<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698476</url>
  </required_header>
  <id_info>
    <org_study_id>IRETB-2012</org_study_id>
    <nct_id>NCT01698476</nct_id>
  </id_info>
  <brief_title>Immune Reconstitution in Tuberculosis Disease</brief_title>
  <acronym>IRETB</acronym>
  <official_title>Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Ethiopia: Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate
      together with standard anti-tuberculosis treatment to significantly improve clinical
      recovery among patients with untreated, active pulmonary tuberculosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite clinical TB score</measure>
    <time_frame>0 (baseline) compared to 8 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A previously described composite clinical TB score will be used to monitor the efficacy of vitamin D and phenylbutyrate treatment among TB patients on standard chemotherapy. The numerical TB score will include self-reported clinical symptoms (cough, night sweats and chest pain) as well as different parameters determined upon clinical examination anemia/conjunctival pallor, haemoptysis, dyspnoea, tachycardia, positive finding at lung auscultation, fever, low body mass index (BMI) and low mid upper arm circumference (MUAC). The TB score will be determined at the time of diagnosis (time point 0) and at 4, 8, 16 and 24 weeks after initiation of antimicrobial treatment with vitamin D and phenylbutyrate. The primary endpoint will be assessed at time point 8 weeks compared to baseline (time point 0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical secondary endpoints</measure>
    <time_frame>0-4, 8, 16 and 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical composite TB score (0, 4, 16, 24 weeks).
Modified clinical composite TB score (0, 4, 8, 16, 24 weeks).
Chest X-ray (0, 4, 8, 16, 24 weeks).
Time to sputum- and/or TB culture conversion (0, 1, 2, 3, 4, 8 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory secondary endpoints</measure>
    <time_frame>0, 4, 8, 16, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peripheral CD4/CD8 T cell counts.
Antibodies in lymphocytes secertions (ALS) (S Ashenafi, Thorax, 2012).
Quantiferon-in-tube TB-gold (QFT).
Plasma levels of vitamin D, LL-37 and also cytokine/chemokine profiles.
Functional studies of immune cells (PBMCs).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Interim analysis</measure>
    <safety_issue>Yes</safety_issue>
    <description>An interim analysis will be performed after approx. 100-150 patients have been included into the study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pulmonary Tuberculosis (TB)</condition>
  <arm_group>
    <arm_group_label>vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)</intervention_name>
    <description>Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.</description>
    <arm_group_label>vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HIV negative patients, adult patients &gt;18 years who has not started anti-TB therapy.

        Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative
        clinical TB cases (defined according to the WHO 2006 criteria for sputum smear-negative TB
        ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment).

        Exclusion Criteria:

        Patients who have already started treatment with anti-TB drugs for more that 5 days.

        HIV-positive patients.

        History of anti-TB treatment in the past 2 years.

        Local extra-pulmonary TB in the absence of lung manifestations.

        Hypercalcaemia (serum calcium &gt; 2.6 mmol/L) identified at baseline.

        Pregnant and breast feeding women.

        Any known liver or kidney function abnormality, malignancy or patients treated with
        cardiac glycosides.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Brighenti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Endale Kassa, MD</last_name>
    <phone>251-911228562</phone>
    <email>endalekassalulu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wondwossen Amogne, MD</last_name>
    <phone>251-911406179</phone>
    <email>wonamogne@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine</name>
      <address>
        <city>Addis Ababa</city>
        <state>Lideta sub city</state>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Endale Kassa, MD</last_name>
      <phone>251-911228562</phone>
      <email>endalekassalulu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Endale Kassa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 2, 2012</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Susanna Brighenti</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>pulmonary TB</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>sodium phenylbutyrate</keyword>
  <keyword>antimicrobial peptides</keyword>
  <keyword>immune response</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
